drugset / Trial / NCT07166549
Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)
NaSingle-groupOpen-labelTreatment
Summary
This study is to provide locally produced, bispecific CD19 CD20 CAR T cells to patients with B-cell lymphoma/leukemia who have no access to commercial CAR T cells or who have relapsed thereafter. The primary objective is to assess the safety of bispecific anti-CD19, anti- CD20 CAR T cell-therapies after lymphodepleting chemotherapy in patients with B cell malignancies with exhausted standard treatment options.
Timeline
- Start
- 2026-06
- Primary completion
- 2028-11
- Completion
- 2028-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bispecific anti-CD19, anti-CD20 CAR T cells | Cell therapy | — | — |
| Background | Bendamustine | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |